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A bradykinin potentiating ~ptide was isolated from a peptic bovine hemoglobin hydrolysate, by the use of reversed-phase high-performance liquid 
chromatography (RP-HPLC). Its primary structure, determined by fast atom bombardment (FAB) and tandem ass pectrometry (MS/MS), was 
identical to fragment 129-134 of the ~.chain of bovine hemoglobin. The bradykinin potency of this peptide, as exhibited by the guinea-pig ileum 
contraction, was significant and comparable with some others previously described. 
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1. INTRODUCTION 
Bradykinin-potentiating activity is found in a large 
number of compounds from various chemical classes 
[1], among these compounds are a number of peptides 
from different sources, especially from protein enzyma- 
tic hydrolysates: tryptic hydrolysates ofplasma proteins 
[1-3] and casein hydrolysates [4,5]. It was found that 
these peptides, which in themselves xhibited no brady- 
kinin activity, enhanced the effect of subsequently 
added synthetic bradykinin on the guinea-pig ileum. 
Previous studies demonstrated that some active pep- 
tides able to potentiate kinin actions also showed their 
ability to inhibit more or less the angiotensin-converting 
enzyme (ACE) in vitro [3,6]. Therefore, although some 
peptides were able to inhibit ACE in vitro, this activity 
did not seem to be the only reason for the potentiation 
they cause [3]. Studies to confirm the possibility of a 
direct action of some potentiating peptides on the kinin 
receptor(s) as well as the specific mechanism of 
potentiation are still under way [7]. Their importance as 
naturally occurring ACE inhibitors are thus discussed. 
In addition, the question why molecules with quite dif- 
ferent structures, i.e. peptides produced by trypsin 
digestion of serum albumin or casein, exert the same 
highly specific effect is not entirely solved [3,8]. 
Recently, a peptide called LVV-hemorphin-6, corre- 
sponding to the sequence at position 32-40 of the t -  
chain of the human hemoglobin, was reported to inhibit 
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ACE activity [9]. This peptide was orif~;nally isolated 
from the human pituitary gland [10]. The normal con- 
centrations of this peptide in plasma has still not been 
determined or similarly its possible importance in blood 
pressure regulation. Apparently, LW-hemorphin-6 is
a naturally occurring peptide which probably could be 
released from hemoglobin i the pituitary by the action 
of a trypsin-like and a chymotrypsin-like enzyme [10]. 
On the basis of this previous observation, we decided 
to investigate if a peptone preparation, obtained in our 
laboratory by peptic hydrolysis of bovine hemoglobin 
[11] could potentiate bradykinin activity towards iso- 
lated guinea-pig ileum. In the present paper the isola- 
tion of a bradykinin-potentiating peptide from this pep 
tic hvdrolysate is described. The active peptide was sep- 
arated from the total hydrolysate, by HPLC and ana- 
lysed by fast atom bombardment mass spectrometry 
(FAB.MS) [121. 
Its structure revealed that it was a fragment of the 
~-chain of hemoslobin. This peptide was then syn- 
thetized in order to verify its activity. 
2. MATERIALS AND METHODS 
2.1. Materials and chemicals 
The synthetic pcptide used in this study was ~ynthefised by C. 
Guillon (Laboratoire de Technologic Enzymatique, University of 
Compi~gnc, Compi~gne, France). Bradykinin, aeetylcholine, anglo- 
tensin II, atropine sulfate and histamine were purchased from Sigma. 
All other chemicals and solvents were of analytical grade from com- 
mercial sources. The guinea-pig ileum contractions were recorded with 
a Washington isotonic transducer. A Waters ystem was used for the 
RP-HPLC separation. The instr,m~nt was ~ulplx~d with a silica ~1 
C-18 semi-preparative column (Waters Delta Pak, 19 x 300 nun. 
particle size 15 ,urn). 
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Fi~, 1. HPLC separation of Peptic hemoglobin hydrolysate on C~ 
Delta Pak column, Bradykinin-potentiating activity co-elated with the 
ab~orbance P ak marked in black, 
2.2. Hydrolysate preparatio~; 
Bovine hemoglobin hydrolysate was obtaine ' 
Peptic proteolysis n an ultr h ~,~ . . . . .  d at Prior-plant scale b 
afi.r.,,,~,, reactor as previously describe~' 
In [1 lJ. Hemoglobin obtained by hemolysing erythrocytes was added 
to water and 4 M hydrochloric acid to obtain 300 liters o? 5% dena. 
tured hemoglobin at pH 2, For peptic digestion, 80 liters of henlo. 
globin were heated to 40oc in a reactor and added to porcine Pepsin 
(240 Anson units}, Hydrolysis lasted 8 h and pH 2 was maintained by a pH star, 
After 8 h, tll~ reactor was connected to ultrafiltration membranes 
(mineral membranes, with nominal moleadar weight cut-off lower 
than 20,000 Da) with an area of0.32 m -~. Ultrafiltration was conducted 
at 40°C for 22 h. OPerating pressures were adjusted in order to keep 
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Fig, 2, HPLC elution of tile bradykinin.potentiating Peptide (p) from 
the active peak collected in Fig, I. The column was a Cj~ Delta Pak, 
a constant ultra~qltration flow (10 l/hi, Incubation volume was main. 
tain~ constant in the ultrafiltration reactor by adding hemolysate, 
The ultrafiltrale was desalted by eleetrodialysis and then atomized. 
The nitrogen content of the Peptidic powder was determined by the 
Kj¢ldahl method and al/owed us to evaluate amounts ol'Peptides ia 
the hydrolysate ~rcater than 90~ (N × 6,25), The Percentage of free amino acids was estimated under 1%. 
2,3, Reversed.phttse high-performance liquid cttromatogruphv (RP. tfPLC) 
RP-HPLC separations were perlbrmed on a silica gel C-18 column 
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Fig. 3. Positive FAB-MS spectrum of the brad.ykinin-potentialing peptid¢. 
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with a mobile phase comprising 10 mM ammonium acetate buffer, pH 
6,0, as eluent A and acetonitrile as eluent B. The flow rate was 12 
ml/min. Samples of hemoglobin hydrolysate were dissolved in buffer 
A (200 mg/ml) filtered through 0.20.urn filters and 500/.tl were injected. 
The linear gradient applied was 0-40% B in 80 rain, Re-equilibration 
at 0% B for 10 rain was performed between each analysis. Eluted 
fractions were collected and freeze.dried prior to mass spectrometry 
analysis and bradykinin-potentiating activity studies. 
2,4, Mass spectrometry analysis 
Mass spectra, generated from FAR.MS and tandem mass spec- 
trometry (MS/MS) of the active peptid¢, were recorded on a four. 
sector 'Concept I r  tandem mass spectrometer (Kratos, Manchester, 
UK), Ions were produced in a standard FAB source by bombarding 
the sample with xenon atoms having a kinetic energy of 8 keV and the 
instrument was operated at an accelerating voltage of 8 kV. 
The peptide was dissolved in water (250 gg of 50/al) and I #l of the 
solution was loaded on the stain!ess teel tip with thioglycerol as 
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Table i
Specificity of the potentiation f bradykinin and other agonists on the 
guinea-pig ileum, Our values are given by m~ans from 3 separate 
experiments 
Agonist Contraction (ram) Potentiating 
(ng/ml bath fluid) factor (P f)  
- Peptid¢ + Peptide 
(3.5 .ug/ml) 
Bradykinin (5) 30 79 2.63 
Angiotensin II (0.75) 79 80 i.01 
Histamine (3) 48 53 1.1 
Acetylcholine (1.5) 128 131 1.02 
matrix. The mass range was scanned at I0 s/decade with a mass 
resolution of 3000. Cesium iodide was the standard for mass calibra- 
tion. In the MS/MS mode, only the ~C component ofthe (M+H)* ion 
is selected by the first two sectors and transmitted into the collision 
region. The collision cell was filled with helium and the collision 
energy was 6 keV. Thus, the peptid¢ sequence was determined from 
the spectrum produced by the collision-induced decomposition (CID) 
of the protonatcd molecule, (M+H)'. 
2.5. Bloassays 
This was done routinely on guinea-pig ileum, The preparation pre- 
viously described [3] was used: a 3--4 cm length of ileum obtained from 
female animals (250 g) was suspended in a 10 ml, 370C bath with 
Tyrode solution containing 1,0 #g of atropine sulfatedml. Pcptid~ to 
bc assayed for bradykinin-potentiatin 8 activity were at first dissolved 
in Tyrode, A certain dose of bradykinin was added either alone or 1 
rain after a peptide, the potentiating effect of which was to b~ deter- 
mined. The effect obtained from addition of the combination was 
compared with the dose--effect curve of bradykinin alone and a 'brady- 
klnin equivalent' of the combination was determined [1]. A potentiat- 
ing factor was calculated as: 
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Fig. 4. CID spectrum of (M÷H) ~ ion of the bradykinin-potentiating l~ptide, and notation of fragment ions, 
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pf = bradFkinin.equivalent of bradykini.n + pcptide 
adrninister~d dose of bradykinin 
3. RESULTS AND DISCUSSION 
The UV-profile from the fractionation of a total pep- 
tic hydrolysate of hemoglobin on the Cls reverse-phase 
column is shown in Fig. 1, As can be seen in Fig. 1, the 
hydrolysate r solved into a large number of peaks cor- 
responding to ~ptides of different molecular size. One 
active fraction, found among several other inactive pep- 
tides, wa~ collected for further purification by RP- 
HPLC under the same conditions. By this technique, the 
active fraction was resolved into two peaks (Fig. 2). The 
major bradykinin-potentiating component eluted at 
13% of acetonitrile. This component was subjected to 
an additional separation on RP-HPLC in order to check 
its purity (not shown). Based on this data, the active 
peptide obtained in significant amounts from the semi- 
preparative RP-HPLC was used throughout the present 
work for mass spectrometry analysis and bradykinin- 
potentiating activity studies. 
Fig. 3 shows the positive FAB-MS spectrum of this 
selected peptide. Accurate relative molecular mass, 
deduced from the m/z value of (M+H) ~ by substraction 
of one mass unit for the attached proton is 603. In order 
to determine the precise amino acid sequence of the 
peptide, tandem MS was performed. In the collision cell 
of the mass spectrometer, the precursor ion fragments 
by CID into structurally significant product ions. Fig. 
4 shows the CID spectrum of the (M+H) + ion and dis- 
plays notation of fragment ions of the peptide according 
to this CID spectrum. Interpretation along the 
fragmentation process results in the recognition of a 
200' 
series of ions indicating the following sequence: Leu- 
Ala-Asn-Val-Ser-Thr. Owing to this amino acid se- 
q~ence, this peptide effectively represents fragment 
129-134 of the s-chain of bovine hemoglobin. 
The specificity of the active peptide for bradykinin 
potentiation is indicated by the results obtained in a set 
of experiments, which showed firstly (Table I) that this 
peptid¢ did not change significantly the effect of several 
smooth muscle agonists uch as acetylcholine, angio- 
tensin II and histamine, whereas the potentiating factor 
is 2.63 in the presence of bradykinin. Then, the data 
presented in Fig. 5 exhibit the additive effect of the 
peptide, when increased amounts of bradykinin were 
added to the guinea-pig ileum in the presence or in the 
absence of this peptide. The points of the curves rep- 
resent the mean __. SD ofdata obtained with three differ- 
ent pieces of smooth muscle. Almost parallel curves 
were obtained in this bradykinin concentration range 
(2-12 ng/ml bath fluid). It must be pointed out that the 
pepfide added by itself involved no contraction of the 
muscle. Furthermore when increased amounts of pep- 
tides were added with a constant concentration of bra- 
dykinin (3.75 ng/ml), the potentiation increased as a 
function of peptide amount (Fig. 6). All these experi- 
ments were performed with the identical synthetic pep- 
tide and gave very similar results (not shown). 
Thus, as far as the specificity is concerned, the peptide 
isolated from bovine hemoglobin gave marked 
potentiations in the range 2-12 ng/ml of bradykinin, 
which is not very far from the results previously de- 
scribed for kinin-potentiating peptides generated from 
human serum protein [3] or casein hydrolysates [4,5]. 
Thus our peptide could be classified along with such 
natural peptides and more precisely with hemoglobin- 
derived biologically active peptides uch as hemorphins. 
Such correlations have already been noted between 
ACE inhibitors from bovine casein hydrolysate and ca- 
somorphin [13]. 
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Fig. 5. Dose-response curves of bmdykinin in the absence (o) and in 
the presence (o) of bradykinin-potentiating peptide (3.5/Jg/ml bath 
fluid) with the $u;~.~.a-pig ileum. 
This could be further extrapolated for hemoglobin- 
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Fig, 6, Dose-dependence of"the potentiating actlvity of bradykinin- 
potentiating peptide in the guinea-pig ileum. Bradykinin was fixed at 
3,75 ns/ml bath fluid. 
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derived peptides since one of them, the opioid active 
fragment LVV-hemorphin-6 [10] was also recently de- 
scribed as an ACE inhibitor [9]. 
A comparison between the ~-chains of bovine and 
human hemoglobin revealed that the hexapeptides lo- 
cated in position 129-134 differ only in one amino acid: 
Leu.Ala-Asn-Val-Ser-Thr (bovine) versus Leu-Ala-Ser- 
Val-Ser-Thr (human). Thus, it would probably be of 
interest o test the specificity of this human hemoglobin- 
derived peptide for bradykinin potentiation. In the pres- 
ent work, the bradykinin potentiating hexapeptide was 
found in a peptic hemoglobin hydrolysate, so that it 
could be produced plausibly during digestion in the 
stoma.oh of foods containing blood [14]. Thus, one may 
speculate, about the formation of this kind of biologi- 
cally active peptide in the gastrointestinal tract, and if 
it would be able to exert a bradykinin potentiation ac- 
tivity in rive. There are now indications that fragments 
of proteins, in the form of small peptides, can cross the 
small intestine to a certain degree and thus gain access 
to peripheral tissue via the circulation [15,16]. 
Further investigations need to be done with our pep- 
tide to examine its influence on ACE activity, in order 
to determine if it exerts its potentiating effect by an 
ACE-dependant or -independant way. 
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